ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular Cancer
Although deemed potentially curative, surgical resection of hepatocellular carcinoma is associated with >70% risk of postoperative relapse. Recurrence is uniquely multifactorial in hepatocellular carcinoma, potentially stemming from metachronous reoccurrence of the original tumor or de novo cancerization. ctDNA may improve personalized risk stratification after resection, a setting where adjuvant immunotherapy has failed to provide survival benefit. See related article by Hu et al., p. 1047.
Authors
- David James Pinato (ORCID: https://orcid.org/0000-0002-3529-0103)
- Antonio D’Alessio (ORCID: https://orcid.org/0000-0002-9164-3671)
- Pasquale Lombardi (ORCID: https://orcid.org/0000-0001-6262-2161)
- Leonardo Brunetti (ORCID: https://orcid.org/0000-0003-2639-4135)
- Claudia Angela Maria Fulgenzi (ORCID: https://orcid.org/0000-0002-5654-9225)
- Aria Torkpour
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Hammersmith Hospital (GB)
- Agostino Gemelli University Polyclinic (IT)
- Campus Bio Medico University Hospital (IT)
- Imperial College London (GB)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3805
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00